<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02051998</url>
  </required_header>
  <id_info>
    <org_study_id>FL 658/4-1</org_study_id>
    <nct_id>NCT02051998</nct_id>
  </id_info>
  <brief_title>Directional Spread in Geographic Atrophy</brief_title>
  <acronym>DSGA</acronym>
  <official_title>Analysis of the Directional Spread of Geographic Atrophy (GA) in Patients With Age-related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in
      industrial countries. In the late stages of the disease, neovascular changes or the
      development of geographic atrophy (GA) may induce severe visual loss. GA is characterized by
      the development of areas of outer retinal atrophy with continuous spread over time that is
      corresponded to an visual field defect for the patient. The pathogenesis is still
      incompletely understood. Despite the break-through in the treatment of neovascular AMD by
      intravitreally administrated vascular endothelial growths factor (VEGF) inhibitors, there is
      yet no treatment available to slow down or halt the disease process in GA. We and others have
      demonstrated that the total GA area progression shows large differences between patients.
      Potential factors influencing differential progression have been intensely studied: While
      neither systemic nor genetic factors have been shown to influence GA progression, ocular
      characteristics such as GA baseline size or phenotypic features of fundus autofluorescence
      (FAF) abnormalities have been identified as risk characteristics for increased GA
      progression. While these previous studies have mainly focused on the characterization of
      total GA area progression, topographic directional spread has not been analyzed and relevant
      predictive markers are yet unknown. There may be large differences in the local GA
      progression. The primary objective of this study is to identify specific characteristics, for
      the local GA progression. The knowledge of such risk factors may help to better understand
      the pathogenesis of GA. The identification of predictive markers will allow for better
      prognostic assessment of the individual disease process. The DSGA study is the extension
      trial of the FAM (Fundus Autofluorescence in Age-related Macular Degeneration) study
      (NCT00393692).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of geographic atrophy size to baseline</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in BCVA from baseline</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Nonexudative Age-related Macular Degeneration</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suitable for the study will be recruited at the University of Bonn, Department of
        Ophthalmology
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Men and women, any race, aged 55 years or older at the baseline visit

          -  If both eyes meet the criteria to be study eye either eye will be included into the
             analysis.

          -  Patient is willing to undergo ocular examinations once every 6 for up to 24 months

        Exclusion Criteria:

          -  The presence or history of CNV (choroidal neovascular membrane) in the study eye

          -  Ocular disease in the study eye that may confound assessment of the retina, other than
             non-exudative AMD (e.g., diabetic retinopathy, uveitis)

          -  Any systemic disease with a limited survival prognosis (e.g., cancer, severe/unstable
             cardiovascular disease).

          -  Any condition that would make adherence to the examination schedule of once every 6
             months for up to 24 months difficult or unlikely, e.g., personality disorder, chronic
             alcoholism, Alzheimer's Disease or drug abuse

          -  Known medical history of allergy or sensitivity to tropicamide or fluorescein dye that
             is clinically relevant in the investigator's opinion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monika Fleckenstein, PD, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, University of Bonn</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank G Holz, Dr. med.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Bonn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maximilian Pfau, Dr. med.</last_name>
    <phone>0049-228-287-11493</phone>
    <email>maximilian.pfau@uni-bonn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monika Fleckenstein, PD, Dr. med.</last_name>
    <phone>0049-228-287-19784</phone>
    <email>monika.fleckenstein@ukb.uni-bonn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Ophthalmology, University of Bonn</name>
      <address>
        <city>Bonn</city>
        <state>NRW</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Czauderna</last_name>
      <phone>0049-228-287-11493</phone>
      <email>Joanna.Czauderna@ukb.uni-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Moritz Lindner, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monika Fleckenstein, PD, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maximilian Pfau</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.augenklinik.uni-bonn.de/</url>
    <description>Webpage of the University Eye Hospital of Bonn</description>
  </link>
  <reference>
    <citation>Holz FG, Bindewald-Wittich A, Fleckenstein M, Dreyhaupt J, Scholl HP, Schmitz-Valckenberg S; FAM-Study Group. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol. 2007 Mar;143(3):463-72. Epub 2006 Dec 22.</citation>
    <PMID>17239336</PMID>
  </reference>
  <reference>
    <citation>Schmitz-Valckenberg S, Bültmann S, Dreyhaupt J, Bindewald A, Holz FG, Rohrschneider K. Fundus autofluorescence and fundus perimetry in the junctional zone of geographic atrophy in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4470-6. Erratum in: Invest Ophthalmol Vis Sci. 2005 Jan;46(1):7.</citation>
    <PMID>15557456</PMID>
  </reference>
  <reference>
    <citation>Fleckenstein M, Adrion C, Schmitz-Valckenberg S, Göbel AP, Bindewald-Wittich A, Scholl HP, Mansmann U, Holz FG; FAM Study Group. Concordance of disease progression in bilateral geographic atrophy due to AMD. Invest Ophthalmol Vis Sci. 2010 Feb;51(2):637-42. doi: 10.1167/iovs.09-3547. Epub 2009 Sep 24. Erratum in: Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1800.</citation>
    <PMID>19797219</PMID>
  </reference>
  <reference>
    <citation>Schmitz-Valckenberg S, Brinkmann CK, Alten F, Herrmann P, Stratmann NK, Göbel AP, Fleckenstein M, Diller M, Jaffe GJ, Holz FG. Semiautomated image processing method for identification and quantification of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011 Sep 29;52(10):7640-6. doi: 10.1167/iovs.11-7457.</citation>
    <PMID>21873669</PMID>
  </reference>
  <reference>
    <citation>Fleckenstein M, Charbel Issa P, Helb HM, Schmitz-Valckenberg S, Finger RP, Scholl HP, Loeffler KU, Holz FG. High-resolution spectral domain-OCT imaging in geographic atrophy associated with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008 Sep;49(9):4137-44. doi: 10.1167/iovs.08-1967. Epub 2008 May 16.</citation>
    <PMID>18487363</PMID>
  </reference>
  <reference>
    <citation>Fleckenstein M, Schmitz-Valckenberg S, Adrion C, Krämer I, Eter N, Helb HM, Brinkmann CK, Charbel Issa P, Mansmann U, Holz FG. Tracking progression with spectral-domain optical coherence tomography in geographic atrophy caused by age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):3846-52. doi: 10.1167/iovs.09-4533. Epub 2010 Mar 31.</citation>
    <PMID>20357194</PMID>
  </reference>
  <reference>
    <citation>Fleckenstein M, Schmitz-Valckenberg S, Martens C, Kosanetzky S, Brinkmann CK, Hageman GS, Holz FG. Fundus autofluorescence and spectral-domain optical coherence tomography characteristics in a rapidly progressing form of geographic atrophy. Invest Ophthalmol Vis Sci. 2011 Jun 1;52(6):3761-6. doi: 10.1167/iovs.10-7021.</citation>
    <PMID>21310912</PMID>
  </reference>
  <reference>
    <citation>Schmitz-Valckenberg S, Fleckenstein M, Helb HM, Charbel Issa P, Scholl HP, Holz FG. In vivo imaging of foveal sparing in geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3915-21. doi: 10.1167/iovs.08-2484. Epub 2009 Apr 1.</citation>
    <PMID>19339734</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2014</study_first_submitted>
  <study_first_submitted_qc>January 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2014</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Dr. Monika Fleckenstein</investigator_full_name>
    <investigator_title>PD, Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Geographic atrophy</keyword>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>Retina</keyword>
  <keyword>Retinal pigment epithelium</keyword>
  <keyword>Optical coherence tomography</keyword>
  <keyword>Scanning laser ophthalmoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

